Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod plus conization versus conization alone for high-grade cervical intraepithelial neoplasia
IRCT20260617069845N1Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Histologic regression of CIN lesions and High-risk HPV clearance. Started Aug 2026; status: recruiting.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on IRCT20260617069845N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260617069845N1.